Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

BOSTON--(BUSINESS WIRE)-- Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming scientific conferences – the American Society of Gene & Cell Therapy (ASGCT) 27^th Annual Meeting, taking place on May 7-11, 2024, in Baltimore, Maryland, and the Protein Engineering Summit (PEGS) Boston Summit 2024, taking place on May 13-17, 2024, in Boston.

“Preclinical data continues to demonstrate exquisite T cell specificity and profound CAR T cell activity with low dose levels of our in vivo Gene Placement System (iGPS^®),” said Kevin Friedman, Ph.D., Chief Executive Officer and Founder of Kelonia. “Combining this platform with our proprietary, fully-human, and highly active BCMA CAR candidate creates a medicine with the potential to transform the treatment of multiple myeloma. With KLN-1010 poised to be the first in vivo CAR-T cell therapy for multiple myeloma, we aim to provide a potentially life-changing solution for patients that need it most. We’re excited to share our latest data at these upcoming conferences, as we continue to advance toward the clinic.”

Details for the panel discussion and presentations are as follows:

ASGCT 27^th Annual Meeting – Scientific Symposium
Panel Session: Moving from Ex Vivo to In Vivo: Challenges and advances in in vivo gene therapy for hematological disorders
Presentation Title: In vivo generation of anti-BCMA CAR T cells for the treatment of multiple myeloma
Panelist: Shannon Grande Contrastano, Ph.D., Vice President of Research at Kelonia
Date and Time: Saturday, May 11, 2024 at 8:00 – 9:45 a.m. ET

PEGS Boston Summit – Therapeutics: In Vivo Cell and Gene Engineering
Discussion Session: In Vivo Engineering of Cells Using Viral Vectors
Presentation Title: In Vivo Engineering Using iGPS Technology
Presenter: Emily Beura, Ph.D., Director of Research at Kelonia
Date and Time: Friday, May 17, 2024 at 9:30 – 10:00 a.m. ET

About Kelonia Therapeutics

Kelonia is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS^®). The company’s elegant, cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modifications to improve in vivo gene transfer efficiency and tropism molecules to facilitate tissue-specific delivery. Initially focused on developing transformational in vivo CAR-T therapies for hematologic cancers, Kelonia is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. Learn more about Kelonia at https://www.keloniatx.com/ and follow us on LinkedIn and Twitter.

iGPS and Kelonia are trademarks of Kelonia Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502664313/en/